Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Dupuytren’s Contracture Market by Type (Type I, Type II, Type III), by Diagnosis (Physical Examination, X-Ray, Others) and by End User (Hospitals, Clinics, Academic and Research, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A11927

Pages: NA

Charts: NA

Tables: NA

Dupuytren's contracture is a condition in which there is difficulty in articulating the fingers of the hand due to formation of tissue knots beneath the skin. The fingers become permanently bent in a flexed position in severe condition. Dupuytren's contracture is not painful and most commonly affects the ring finger followed by the little and middle fingers. It has a higher rate in males over the age of 50. The exact causes of Dupuytren's contracture are unknown, however, the risk factors include thyroid problems, alcoholism, liver disease, smoking, diabetes, epilepsy, previous hand trauma, and family history. The surgery is performed when the proximal interphalangeal joint contracture exceeds 20 degrees or the metacarpophalangeal joint contracture exceeds 40 degrees. The less severe forms of the Dupuytren's contracture disease are treated with steroid treatment and physiotherapy.

COVID-19 Impact Analysis

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the Dupuytren’s contracture market.

Top Impacting Factors

Increase in geriatric population leading to rise in patient population is the key driver of the global Dupuytren’s contracture market. In addition, rise in cardiac cases such as heart attack, other factors includes cancer, kidney failure, end-stage lung cancer, and hypothyroidism boosts the market growth. Moreover, rise in screening and increase in healthcare expenditure propel the growth of the Dupuytren’s contracture market.

In addition, rise in awareness about health and government initiatives to improve healthcare infrastructure are some factors that boosts the market growth. Moreover, increase in awareness about cardiac diseases can propel the growth of the market.

Furthermore, ongoing research & developments for creating efficient and availability of cost-effective treatments boosts the market  growth.

However, complications and risk associated with Dupuytren’s contracture surgery and invasive nature of the treatment restrain the growth of the market.

Market Trends

New Product Launches to Flourish the Market

In September 2019, Endo International Plc. announced four new studies of XIAFLEX (collagenase clostridium histolyticum), including real-world data, for the treatment of Dupuytren's contracture. XIAFLEX is indicated for the treatment of adult patients with Dupuytren's contracture with a palpable cord.

In April 2018, Paladin Labs Inc. announced the launch of a new indication for XIAFLEX (collagenase clostridium histolyticum), the first and only Health Canada-approved treatment for appropriate patients with peyronie's disease with palpable plaque and curvature deformity of at least 30 degrees at the start.

Key Benefits of the Report

  • This study presents the analytical depiction of the Dupuytren’s contracture market industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
  • The current market is quantitatively analyzed to highlight the market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Dupuytren’s Contracture Market Report

  • Which are the leading players active in the Dupuytren’s contracture market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What is Dupuytren’s contracture market?
  • What is Dupuytren’s contracture market prediction in the future?
  • Who are the leading global players in the Dupuytren’s contracture market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the Dupuytren’s contracture market report?

 Key Market Segments

  • By Type
    • Type I
    • Type II
    • Type III
  • By Diagnosis
    • Physical Examination
    • X-Ray
    • Others
  • By End User
    • Hospitals
    • Clinics
    • Academic and Research
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • West-Ward Pharmaceuticals
  • Bristol-Meyers Squibb Co.
  • Fresenius Kabi AG
  • Nantong Jinghua Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Merck Sharp & Dohme Corp.
  • Actiza Pharmaceutical Private Limited
  • Endo International plc.
  • Spear Pharmacueticals

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: DUPUYTREN’S CONTRACTURE MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Type I

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Type II

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Type III

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: DUPUYTREN’S CONTRACTURE MARKET, BY DIAGNOSIS

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Diagnosis

    • 5.2. Physical Examination

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. X-Ray

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Others

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: DUPUYTREN’S CONTRACTURE MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Hospitals

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Clinics

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Academic And Research

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Others

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

  • CHAPTER 7: DUPUYTREN’S CONTRACTURE MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Type

      • 7.2.3. Market Size and Forecast, By Diagnosis

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Dupuytren’s Contracture Market

        • 7.2.6.1. Market Size and Forecast, By Type
        • 7.2.6.2. Market Size and Forecast, By Diagnosis
        • 7.2.6.3. Market Size and Forecast, By End User

      • 7.2.7. Canada Dupuytren’s Contracture Market

        • 7.2.7.1. Market Size and Forecast, By Type
        • 7.2.7.2. Market Size and Forecast, By Diagnosis
        • 7.2.7.3. Market Size and Forecast, By End User

      • 7.2.8. Mexico Dupuytren’s Contracture Market

        • 7.2.8.1. Market Size and Forecast, By Type
        • 7.2.8.2. Market Size and Forecast, By Diagnosis
        • 7.2.8.3. Market Size and Forecast, By End User

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Type

      • 7.3.3. Market Size and Forecast, By Diagnosis

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Dupuytren’s Contracture Market

        • 7.3.6.1. Market Size and Forecast, By Type
        • 7.3.6.2. Market Size and Forecast, By Diagnosis
        • 7.3.6.3. Market Size and Forecast, By End User

      • 7.3.7. Germany Dupuytren’s Contracture Market

        • 7.3.7.1. Market Size and Forecast, By Type
        • 7.3.7.2. Market Size and Forecast, By Diagnosis
        • 7.3.7.3. Market Size and Forecast, By End User

      • 7.3.8. Italy Dupuytren’s Contracture Market

        • 7.3.8.1. Market Size and Forecast, By Type
        • 7.3.8.2. Market Size and Forecast, By Diagnosis
        • 7.3.8.3. Market Size and Forecast, By End User

      • 7.3.9. Spain Dupuytren’s Contracture Market

        • 7.3.9.1. Market Size and Forecast, By Type
        • 7.3.9.2. Market Size and Forecast, By Diagnosis
        • 7.3.9.3. Market Size and Forecast, By End User

      • 7.3.10. UK Dupuytren’s Contracture Market

        • 7.3.10.1. Market Size and Forecast, By Type
        • 7.3.10.2. Market Size and Forecast, By Diagnosis
        • 7.3.10.3. Market Size and Forecast, By End User

      • 7.3.11. Russia Dupuytren’s Contracture Market

        • 7.3.11.1. Market Size and Forecast, By Type
        • 7.3.11.2. Market Size and Forecast, By Diagnosis
        • 7.3.11.3. Market Size and Forecast, By End User

      • 7.3.12. Rest Of Europe Dupuytren’s Contracture Market

        • 7.3.12.1. Market Size and Forecast, By Type
        • 7.3.12.2. Market Size and Forecast, By Diagnosis
        • 7.3.12.3. Market Size and Forecast, By End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Type

      • 7.4.3. Market Size and Forecast, By Diagnosis

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Dupuytren’s Contracture Market

        • 7.4.6.1. Market Size and Forecast, By Type
        • 7.4.6.2. Market Size and Forecast, By Diagnosis
        • 7.4.6.3. Market Size and Forecast, By End User

      • 7.4.7. Japan Dupuytren’s Contracture Market

        • 7.4.7.1. Market Size and Forecast, By Type
        • 7.4.7.2. Market Size and Forecast, By Diagnosis
        • 7.4.7.3. Market Size and Forecast, By End User

      • 7.4.8. India Dupuytren’s Contracture Market

        • 7.4.8.1. Market Size and Forecast, By Type
        • 7.4.8.2. Market Size and Forecast, By Diagnosis
        • 7.4.8.3. Market Size and Forecast, By End User

      • 7.4.9. South Korea Dupuytren’s Contracture Market

        • 7.4.9.1. Market Size and Forecast, By Type
        • 7.4.9.2. Market Size and Forecast, By Diagnosis
        • 7.4.9.3. Market Size and Forecast, By End User

      • 7.4.10. Australia Dupuytren’s Contracture Market

        • 7.4.10.1. Market Size and Forecast, By Type
        • 7.4.10.2. Market Size and Forecast, By Diagnosis
        • 7.4.10.3. Market Size and Forecast, By End User

      • 7.4.11. Thailand Dupuytren’s Contracture Market

        • 7.4.11.1. Market Size and Forecast, By Type
        • 7.4.11.2. Market Size and Forecast, By Diagnosis
        • 7.4.11.3. Market Size and Forecast, By End User

      • 7.4.12. Malaysia Dupuytren’s Contracture Market

        • 7.4.12.1. Market Size and Forecast, By Type
        • 7.4.12.2. Market Size and Forecast, By Diagnosis
        • 7.4.12.3. Market Size and Forecast, By End User

      • 7.4.13. Indonesia Dupuytren’s Contracture Market

        • 7.4.13.1. Market Size and Forecast, By Type
        • 7.4.13.2. Market Size and Forecast, By Diagnosis
        • 7.4.13.3. Market Size and Forecast, By End User

      • 7.4.14. Rest of Asia Pacific Dupuytren’s Contracture Market

        • 7.4.14.1. Market Size and Forecast, By Type
        • 7.4.14.2. Market Size and Forecast, By Diagnosis
        • 7.4.14.3. Market Size and Forecast, By End User

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Type

      • 7.5.3. Market Size and Forecast, By Diagnosis

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Dupuytren’s Contracture Market

        • 7.5.6.1. Market Size and Forecast, By Type
        • 7.5.6.2. Market Size and Forecast, By Diagnosis
        • 7.5.6.3. Market Size and Forecast, By End User

      • 7.5.7. South Africa Dupuytren’s Contracture Market

        • 7.5.7.1. Market Size and Forecast, By Type
        • 7.5.7.2. Market Size and Forecast, By Diagnosis
        • 7.5.7.3. Market Size and Forecast, By End User

      • 7.5.8. Saudi Arabia Dupuytren’s Contracture Market

        • 7.5.8.1. Market Size and Forecast, By Type
        • 7.5.8.2. Market Size and Forecast, By Diagnosis
        • 7.5.8.3. Market Size and Forecast, By End User

      • 7.5.9. UAE Dupuytren’s Contracture Market

        • 7.5.9.1. Market Size and Forecast, By Type
        • 7.5.9.2. Market Size and Forecast, By Diagnosis
        • 7.5.9.3. Market Size and Forecast, By End User

      • 7.5.10. Argentina Dupuytren’s Contracture Market

        • 7.5.10.1. Market Size and Forecast, By Type
        • 7.5.10.2. Market Size and Forecast, By Diagnosis
        • 7.5.10.3. Market Size and Forecast, By End User

      • 7.5.11. Rest of LAMEA Dupuytren’s Contracture Market

        • 7.5.11.1. Market Size and Forecast, By Type
        • 7.5.11.2. Market Size and Forecast, By Diagnosis
        • 7.5.11.3. Market Size and Forecast, By End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Bristol-Meyers Squibb Co.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Fresenius Kabi AG

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Merck Sharp And Dohme Corp.

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Pfizer Inc.

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. West-Ward Pharmaceuticals

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Spear Pharmacueticals

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Actiza Pharmaceutical Private Limited

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Nantong Jinghua Pharmaceutical Co., Ltd.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Endo International Plc.

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL DUPUYTREN’S CONTRACTURE MARKET, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL DUPUYTREN’S CONTRACTURE MARKET FOR TYPE I, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL DUPUYTREN’S CONTRACTURE MARKET FOR TYPE II, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL DUPUYTREN’S CONTRACTURE MARKET FOR TYPE III, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL DUPUYTREN’S CONTRACTURE MARKET, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL DUPUYTREN’S CONTRACTURE MARKET FOR PHYSICAL EXAMINATION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL DUPUYTREN’S CONTRACTURE MARKET FOR X-RAY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL DUPUYTREN’S CONTRACTURE MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL DUPUYTREN’S CONTRACTURE MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL DUPUYTREN’S CONTRACTURE MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL DUPUYTREN’S CONTRACTURE MARKET FOR CLINICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL DUPUYTREN’S CONTRACTURE MARKET FOR ACADEMIC AND RESEARCH, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL DUPUYTREN’S CONTRACTURE MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL DUPUYTREN’S CONTRACTURE MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. NORTH AMERICA DUPUYTREN’S CONTRACTURE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. NORTH AMERICA DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 18. NORTH AMERICA DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 19. U.S. DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 20. U.S. DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 21. U.S. DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 22. CANADA DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 23. CANADA DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 24. CANADA DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 25. MEXICO DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 26. MEXICO DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 27. MEXICO DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 28. EUROPE DUPUYTREN’S CONTRACTURE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 29. EUROPE DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 30. EUROPE DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 31. EUROPE DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 32. FRANCE DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 33. FRANCE DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 34. FRANCE DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 35. GERMANY DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 36. GERMANY DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 37. GERMANY DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 38. ITALY DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 39. ITALY DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 40. ITALY DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 41. SPAIN DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 42. SPAIN DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 43. SPAIN DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 44. UK DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 45. UK DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 46. UK DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 47. RUSSIA DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 48. RUSSIA DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 49. RUSSIA DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 50. REST OF EUROPE DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 51. REST OF EUROPE DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 52. REST OF EUROPE DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 53. ASIA-PACIFIC DUPUYTREN’S CONTRACTURE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 54. ASIA-PACIFIC DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 55. ASIA-PACIFIC DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 56. ASIA-PACIFIC DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 57. CHINA DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 58. CHINA DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 59. CHINA DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 60. JAPAN DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 61. JAPAN DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 62. JAPAN DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 63. INDIA DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 64. INDIA DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 65. INDIA DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 66. SOUTH KOREA DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 67. SOUTH KOREA DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 68. SOUTH KOREA DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 69. AUSTRALIA DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 70. AUSTRALIA DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 71. AUSTRALIA DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 72. THAILAND DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 73. THAILAND DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 74. THAILAND DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 75. MALAYSIA DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 76. MALAYSIA DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 77. MALAYSIA DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 78. INDONESIA DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 79. INDONESIA DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 80. INDONESIA DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 81. REST OF ASIA PACIFIC DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 84. LAMEA DUPUYTREN’S CONTRACTURE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 85. LAMEA DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 86. LAMEA DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 87. LAMEA DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 88. BRAZIL DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 89. BRAZIL DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 90. BRAZIL DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 91. SOUTH AFRICA DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 92. SOUTH AFRICA DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 93. SOUTH AFRICA DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 94. SAUDI ARABIA DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 95. SAUDI ARABIA DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 96. SAUDI ARABIA DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 97. UAE DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 98. UAE DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 99. UAE DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 100. ARGENTINA DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 101. ARGENTINA DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 102. ARGENTINA DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 103. REST OF LAMEA DUPUYTREN’S CONTRACTURE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 104. REST OF LAMEA DUPUYTREN’S CONTRACTURE, BY DIAGNOSIS, 2025-2033 ($MILLION)
  • TABLE 105. REST OF LAMEA DUPUYTREN’S CONTRACTURE, BY END USER, 2025-2033 ($MILLION)
  • TABLE 106. BRISTOL-MEYERS SQUIBB CO.: KEY EXECUTIVES
  • TABLE 107. BRISTOL-MEYERS SQUIBB CO.: COMPANY SNAPSHOT
  • TABLE 108. BRISTOL-MEYERS SQUIBB CO.: OPERATING SEGMENTS
  • TABLE 109. BRISTOL-MEYERS SQUIBB CO.: PRODUCT PORTFOLIO
  • TABLE 110. BRISTOL-MEYERS SQUIBB CO.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 111. FRESENIUS KABI AG: KEY EXECUTIVES
  • TABLE 112. FRESENIUS KABI AG: COMPANY SNAPSHOT
  • TABLE 113. FRESENIUS KABI AG: OPERATING SEGMENTS
  • TABLE 114. FRESENIUS KABI AG: PRODUCT PORTFOLIO
  • TABLE 115. FRESENIUS KABI AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116. MERCK SHARP AND DOHME CORP.: KEY EXECUTIVES
  • TABLE 117. MERCK SHARP AND DOHME CORP.: COMPANY SNAPSHOT
  • TABLE 118. MERCK SHARP AND DOHME CORP.: OPERATING SEGMENTS
  • TABLE 119. MERCK SHARP AND DOHME CORP.: PRODUCT PORTFOLIO
  • TABLE 120. MERCK SHARP AND DOHME CORP.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 121. PFIZER INC.: KEY EXECUTIVES
  • TABLE 122. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 123. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 124. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 125. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 126. WEST-WARD PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 127. WEST-WARD PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 128. WEST-WARD PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 129. WEST-WARD PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 130. WEST-WARD PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 131. SPEAR PHARMACUETICALS: KEY EXECUTIVES
  • TABLE 132. SPEAR PHARMACUETICALS: COMPANY SNAPSHOT
  • TABLE 133. SPEAR PHARMACUETICALS: OPERATING SEGMENTS
  • TABLE 134. SPEAR PHARMACUETICALS: PRODUCT PORTFOLIO
  • TABLE 135. SPEAR PHARMACUETICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 136. ACTIZA PHARMACEUTICAL PRIVATE LIMITED: KEY EXECUTIVES
  • TABLE 137. ACTIZA PHARMACEUTICAL PRIVATE LIMITED: COMPANY SNAPSHOT
  • TABLE 138. ACTIZA PHARMACEUTICAL PRIVATE LIMITED: OPERATING SEGMENTS
  • TABLE 139. ACTIZA PHARMACEUTICAL PRIVATE LIMITED: PRODUCT PORTFOLIO
  • TABLE 140. ACTIZA PHARMACEUTICAL PRIVATE LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 141. NANTONG JINGHUA PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
  • TABLE 142. NANTONG JINGHUA PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
  • TABLE 143. NANTONG JINGHUA PHARMACEUTICAL CO., LTD.: OPERATING SEGMENTS
  • TABLE 144. NANTONG JINGHUA PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 145. NANTONG JINGHUA PHARMACEUTICAL CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 146. ENDO INTERNATIONAL PLC.: KEY EXECUTIVES
  • TABLE 147. ENDO INTERNATIONAL PLC.: COMPANY SNAPSHOT
  • TABLE 148. ENDO INTERNATIONAL PLC.: OPERATING SEGMENTS
  • TABLE 149. ENDO INTERNATIONAL PLC.: PRODUCT PORTFOLIO
  • TABLE 150. ENDO INTERNATIONAL PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL DUPUYTREN’S CONTRACTURE MARKET SEGMENTATION
  • FIGURE 2. GLOBAL DUPUYTREN’S CONTRACTURE MARKET
  • FIGURE 3. SEGMENTATION DUPUYTREN’S CONTRACTURE MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN DUPUYTREN’S CONTRACTURE MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALDUPUYTREN’S CONTRACTURE MARKET
  • FIGURE 11. DUPUYTREN’S CONTRACTURE MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. DUPUYTREN’S CONTRACTURE MARKET FOR TYPE I, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. DUPUYTREN’S CONTRACTURE MARKET FOR TYPE II, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. DUPUYTREN’S CONTRACTURE MARKET FOR TYPE III, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. DUPUYTREN’S CONTRACTURE MARKET SEGMENTATION, BY BY DIAGNOSIS
  • FIGURE 16. DUPUYTREN’S CONTRACTURE MARKET FOR PHYSICAL EXAMINATION, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. DUPUYTREN’S CONTRACTURE MARKET FOR X-RAY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. DUPUYTREN’S CONTRACTURE MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. DUPUYTREN’S CONTRACTURE MARKET SEGMENTATION, BY BY END USER
  • FIGURE 20. DUPUYTREN’S CONTRACTURE MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. DUPUYTREN’S CONTRACTURE MARKET FOR CLINICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. DUPUYTREN’S CONTRACTURE MARKET FOR ACADEMIC AND RESEARCH, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. DUPUYTREN’S CONTRACTURE MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 25. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 26. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 27. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 28. COMPETITIVE DASHBOARD
  • FIGURE 29. COMPETITIVE HEATMAP: DUPUYTREN’S CONTRACTURE MARKET
  • FIGURE 30. TOP PLAYER POSITIONING, 2024
  • FIGURE 31. BRISTOL-MEYERS SQUIBB CO.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 32. BRISTOL-MEYERS SQUIBB CO.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 33. BRISTOL-MEYERS SQUIBB CO.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 34. FRESENIUS KABI AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 35. FRESENIUS KABI AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 36. FRESENIUS KABI AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 37. MERCK SHARP AND DOHME CORP.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. MERCK SHARP AND DOHME CORP.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. MERCK SHARP AND DOHME CORP.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. PFIZER INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. PFIZER INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. WEST-WARD PHARMACEUTICALS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. WEST-WARD PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. WEST-WARD PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. SPEAR PHARMACUETICALS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. SPEAR PHARMACUETICALS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. SPEAR PHARMACUETICALS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. ACTIZA PHARMACEUTICAL PRIVATE LIMITED: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. ACTIZA PHARMACEUTICAL PRIVATE LIMITED: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. ACTIZA PHARMACEUTICAL PRIVATE LIMITED: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. NANTONG JINGHUA PHARMACEUTICAL CO., LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. NANTONG JINGHUA PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. NANTONG JINGHUA PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 55. ENDO INTERNATIONAL PLC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 56. ENDO INTERNATIONAL PLC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 57. ENDO INTERNATIONAL PLC.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Dupuytren’s Contracture Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved